222 S. Rainbow Blvd
Suite 203
Las Vegas, Nevada 89145

Our Mission

The National Hemophilia Foundation (NHF) Nevada Chapter is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.

News & Events

uniQure recently announced that their commercialization and license agreement with CSL Behring  for their investigational hemophilia B gene therapy was finally closed on May 5, 2021 – the agreement had been pending the completion of a series of antitrust reviews in the U.S., Australia, and the U.K.

Findings from a recently published study in the Journal of Anesthesia suggest that pregnant patients with hemophilia whose factor VIII or IX levels drop below 50% at the time of receiving neuraxial anesthesia are more likely to experience postpartum complications.

Hemophilia Treatment Centers (HTCs) across the United States are participating in the 2021 National HTC Patient Satisfaction Survey. If you, or someone you care for, had contact with the HTC in 2020, they want to hear from you! You can take the survey online at www.htcsurvey.com, or fill out the paper survey you received in the mail. The survey closes on June 30, 2021.

Advertisements

222 S. Rainbow Blvd
Suite 203
Las Vegas, Nevada 89145

© Nevada Chapter of the National Hemophilia Foundation 2021

Powered by Firespring